{"nctId":"NCT00373334","briefTitle":"Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)","startDateStruct":{"date":"2006-08"},"conditions":["Gastroesophageal Reflux Disease","GERD","Heartburn"],"count":138,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: nizatidine (axid)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: nizatidine (axid)"]},{"label":"3","type":"SHAM_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"nizatidine (axid)","otherNames":[]},{"name":"nizatidine (axid)","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female outpatients age 30 days up to 1 year at Visit 1.\n* Subjects must have a documented medical diagnosis of gastroesophageal reflux disease (GERD), confirmed by either endoscopy or pH monitoring, or by evaluation of baseline symptoms.\n* Subjects must be greater than the 3rd percentile of weight and height for their age.\n* Parents/guardians are competent and willing to provide consent and sign and date the institutional review board (IRB) approved consent form.\n* Parents/guardians are willing to adhere to study requirements, including applying the conservative GERD management methods.\n* Conservative GERD management methods have failed to adequately control GERD symptoms by Visit 2.\n* Parent/guardian and infant live in the same household.\n* Qualifying caregiver questionnaire score at Visits 1 \\& 2.\n\nExclusion Criteria:\n\n* Any known esophageal disease or disorder, other than reflux esophagitis.\n* Any active gastroduodenal ulceration, or clinical or endoscopic evidence of active gastrointestinal bleeding.\n* Any prior esophageal or gastric surgery.\n* Concurrent serious systemic disorders, including chronic respiratory disease, chronic neurologic disease, chronic renal disease, chronic liver disease.\n* Subjects with clinically significant abnormal laboratory findings at screening.\n* Premature infants \\< 37 weeks gestation at birth.\n* Infants with prior neonatal intensive care unit admission for any reason.\n* Hematemesis or apparent life-threatening events (ALTE).\n* Concurrent treatment with any chronic medication except by permission of the study sponsor.\n* Treatment with a histamine 2 receptor antagonist (H2RA), antacid, sucralfate, prostaglandin, or motility agent within 3 days before Visit 1; treatment with a proton pump inhibitor within 7 days before Visit 1.\n* Requirement or likely requirement for a medical procedure or surgery during the study.\n* Known hypersensitivity to an H2RA including nizatidine.\n* Receipt of any investigational agent within the previous 30 days before randomization.\n* Poor medical or psychiatric risks for therapy with an investigational drug, in the opinion of the investigator.\n* Any condition in parent/guardian associated with poor subject compliance e.g., substance abuse); inability of parent/guardian to return for scheduled visits with their child.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Days","maximumAge":"1 Year","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Success","description":"The I-GERQ-R contains 12 questions assessing gastroesophageal reflux disease (GERD) frequency and severity. A low I-GERQ-R score (minimum = 0) indicates minimal symptoms and a high I-GERQ-R score (maximum = 42) indicates more frequent and/or severe symptoms. Success is defined as a reduction in I-GERQ-R score of at least 5 points from baseline, provided a subject did not discontinue due to lack of efficacy or adverse event, and had been treated for at least 4 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator Assessment of Gastroesophageal Reflux Disease (GERD) Relief","description":"Subjective investigator assessment of GERD relief - rating categories were BETTER, NO CHANGE, or WORSE from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator Assessment of Gastroesophageal Reflux Disease (GERD) Severity","description":"Subjective investigator assessment of GERD severity - rating categories were NONE, MILD, MODERATE, or SEVERE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["upper respiratory tract infection","otitis media","gastroesophageal reflux disease","Diarrhea","bronchiolitis"]}}}